| human | Q5 |
| P227 | GND ID | 1093190019 |
| P2671 | Google Knowledge Graph ID | /g/11ghrc3lbk |
| P1153 | Scopus author ID | 7004310816 |
| P214 | VIAF ID | 430145910085127021707 |
| P10832 | WorldCat Entities ID | E39PBJfrK8rpTTkMRxV9C9BXVC |
| P108 | employer | University of Basel | Q372608 |
| P735 | given name | Christian | Q18001597 |
| Christian | Q18001597 | ||
| P2650 | interested in | ophthalmology | Q161437 |
| P106 | occupation | academic | Q3400985 |
| ophthalmologist | Q12013238 | ||
| P21 | sex or gender | male | Q6581097 |
| Q95562551 | Q95562551 |
| Q53538006 | A longitudinal comparison of spectral-domain optical coherence tomography and fundus autofluorescence in geographic atrophy. |
| Q33874677 | A systematic comparison of spectral-domain optical coherence tomography and fundus autofluorescence in patients with geographic atrophy |
| Q89493016 | ASSESSMENT OF DRUSEN AND OTHER RETINAL DEGENERATIVE CHANGES IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS |
| Q45976607 | Alterations of intraretinal layers in acute central serous chorioretinopathy. |
| Q33504810 | Automatic and manual segmentation of healthy retinas using high-definition optical coherence tomography |
| Q47994476 | Baseline Optical Coherence Tomography Findings as Outcome Predictors after Switching from Ranibizumab to Aflibercept in Neovascular Age-Related Macular Degeneration following a Treat-and-Extend Regimen |
| Q55982757 | Central serous chorioretinopathy |
| Q87056897 | Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration |
| Q51394742 | Comparing ranibizumab monotherapy and combination with single photodynamic therapy in wet AMD: retreatment and morphologic results. |
| Q46753694 | Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration |
| Q30238478 | Considerations for management of patients with diabetic macular edema: Optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration. |
| Q44122206 | Human connective tissue growth factor mRNA expression of epiretinal and subretinal fibrovascular membranes: a report of three cases |
| Q51800250 | INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB: A Treat-and-Extend Trial. |
| Q33521617 | In vivo retinal morphology after grid laser treatment in diabetic macular edema |
| Q50454002 | Intraindividual comparison of color perception and contrast sensitivity with and without a blue light-filtering intraocular lens |
| Q50006249 | Low-Energy Stereotactic Radiotherapy for Treatment of Exudative Age-Related Macular Degeneration in a Treat-and-Extend Regimen |
| Q88415044 | May consultation #4 |
| Q31095736 | Measurement procedures in confocal choroidal laser Doppler flowmetry |
| Q84997561 | Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR |
| Q37552779 | Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response |
| Q82316478 | Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy |
| Q24658546 | Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study |
| Q86179684 | Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 months of retreatment and vision outcomes from a randomized study |
| Q53255176 | Report on Norrie's cytology. |
| Q51673784 | Retinal thickness and volume measurements in diabetic macular edema: a comparison of four optical coherence tomography systems. |
| Q34649129 | Septin expression in proliferative retinal membranes |
| Q35589410 | Sildenafil induces retinal vasodilatation in healthy subjects |
| Q53138974 | Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study. |
| Christian Prünte | wikipedia |
Search more.